Navigation Links
OptiNose presents data on highly effective migraine treatment
Date:6/28/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 1CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 2CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 1National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 2National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 4Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 1Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 2Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 3